RESUMEN
The synthesis of affinity matrices for 6-aminophenanthridine (6AP) and 2,6-dichlorobenzylidenaminoguanidine (Guanabenz, GA), two unrelated prion inhibitors, is described. In both cases, the same simple spacer, epsilon-aminocaproylaminopentanol, was introduced by a Mitsunobu reaction and the choice of the anchoring position of the linker was determined by the study of the residual antiprion activity of the corresponding 6AP or GA conjugates. Very recently, these two affinity matrices were used for chromatography assays leading to the identification of ribosome (via the rRNA) as a common target of these two antiprion drugs. Here, we show, using competition experiments with Quinacrine (QC) and Chlorpromazine (CPZ), two other antiprion drugs, that QC, but not CPZ, may also directly target the rRNA.
Asunto(s)
Cromatografía de Afinidad , Guanabenzo/síntesis química , Guanabenzo/metabolismo , Fenantridinas/síntesis química , Fenantridinas/metabolismo , Priones/antagonistas & inhibidores , Unión Competitiva , Clorpromazina/metabolismo , Guanabenzo/química , Guanabenzo/farmacología , Microesferas , Fenantridinas/química , Fenantridinas/farmacología , Quinacrina/metabolismo , ARN Ribosómico/metabolismo , Ribosomas/metabolismo , Sefarosa/químicaRESUMEN
Protein phosphorylation regulates virtually all biological processes. Although protein kinases are popular drug targets, targeting protein phosphatases remains a challenge. Here, we describe Sephin1 (selective inhibitor of a holophosphatase), a small molecule that safely and selectively inhibited a regulatory subunit of protein phosphatase 1 in vivo. Sephin1 selectively bound and inhibited the stress-induced PPP1R15A, but not the related and constitutive PPP1R15B, to prolong the benefit of an adaptive phospho-signaling pathway, protecting cells from otherwise lethal protein misfolding stress. In vivo, Sephin1 safely prevented the motor, morphological, and molecular defects of two otherwise unrelated protein-misfolding diseases in mice, Charcot-Marie-Tooth 1B, and amyotrophic lateral sclerosis. Thus, regulatory subunits of phosphatases are drug targets, a property exploited here to safely prevent two protein misfolding diseases.
Asunto(s)
Inhibidores Enzimáticos/farmacología , Guanabenzo/análogos & derivados , Proteína Fosfatasa 1/antagonistas & inhibidores , Deficiencias en la Proteostasis/tratamiento farmacológico , Deficiencias en la Proteostasis/prevención & control , Esclerosis Amiotrófica Lateral/tratamiento farmacológico , Esclerosis Amiotrófica Lateral/metabolismo , Esclerosis Amiotrófica Lateral/patología , Animales , Células Cultivadas , Enfermedad de Charcot-Marie-Tooth/tratamiento farmacológico , Enfermedad de Charcot-Marie-Tooth/metabolismo , Enfermedad de Charcot-Marie-Tooth/patología , Modelos Animales de Enfermedad , Estrés del Retículo Endoplásmico/efectos de los fármacos , Inhibidores Enzimáticos/metabolismo , Inhibidores Enzimáticos/farmacocinética , Inhibidores Enzimáticos/toxicidad , Guanabenzo/síntesis química , Guanabenzo/metabolismo , Guanabenzo/farmacología , Guanabenzo/toxicidad , Células HeLa , Humanos , Ratones , Ratones Transgénicos , Terapia Molecular Dirigida , Fosforilación , Pliegue de Proteína , Transducción de SeñalRESUMEN
Guanabenz, [(2,6-dichlorobenzylidene)amino]guanidine, acetate was shown to be the E-isomer. It decomposed to form the Z-isomer, 2,6-dichlorobenzaldehyde, aminoguanidine, and 2,6-dichlorobenzaldehyde semicarbazone. A stability-indicating assay for the intact drug in the presence of all of its decomposition products by the use of UV spectroscopy is presented.